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Summary Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m-2
as a 1 5-min intravenous infusion at 21 -day intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with
disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles were given (median two, range one to four). The drug
was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in
only one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive
as second line therapy for small-cell lung cancer.
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Lung cancer is now the commonest cause of cancer death in both
men and women in the Western world (Parker et al, 1996). Small-
cell lung cancer accounts for up to 25% of cases. It is initially
chemosensitive, but the majority of patients die from resistant
disease within 2 years of diagnosis. There is therefore an urgent
need for better treatment for small-cell lung cancer.
Raltitrexed ('Tomudex', ZDl694) is a potent and specific
inhibitor of thymidylate synthase, the enzyme that catalyses the
formation of thymidylate from deoxyuridine monophosphate
(Jackman et al, 1991). It has broad-spectrum activity in experi-
mental studies and has shown promising activity in phase I and II
studies in various tumours, including colorectal and breast cancers
(Cunningham et al, 1995, 1996; Clarke et al, 1996). The maximum
tolerated dose determined in phase I studies was 3.5 mg m-2 when
the drug was given at 3-week intervals, although one USA study
obtained a maximum tolerated dose of 4.5 mg m-2 (Sorensen et al,
1994). The dose-limiting toxicities in these studies were diarrhoea
and myelosuppression. We tested raltitrexed for activity in
advanced small-cell lung cancer.
PATIENTS AND METHODS
Patients with histologically confirmed small-cell lung cancer and
measurable or evaluable lesions with documented progression
were eligible for the study. Patients who had received prior
chemotherapy for small-cell lung cancer were included only if
they had achieved a response to it (i.e. tumours refractory to
primary treatment were excluded). Patients with brain metastases,
prior malignant disease or other uncontrolled medical conditions
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were excluded. No chemotherapy or radiotherapy was permitted in
the 4 weeks before study entry, and patients were required to have
a life expectancy of greater than 3 months. Systemic steroids and
folic acid supplements were not permitted during the study.
Written informed consent was obtained. Patients underwent
standard staging investigations before starting treatment.
Raltitrexed was supplied in the form of a 1.0 mg ml-' solution
by Zeneca Pharma, Wilmslow, UK. Treatment was given at a dose
of 3.0 mg m-2 as a 15-min intravenous infusion at 21-day intervals.
Drug administration was postponed if full haematological
recovery (WBC > 4 x 109 1-1, platelets > 100 x 109 1-') from the
previous cycle had not occurred. Dose reductions were planned
for . WHO grade 2 diarrhoea, > WHO grade 3 haematological
toxicity or both in combination.
RESULTS
Patient characteristics
Twenty-one patients were enrolled in the study and included in this
analysis. Their status at entry is shown in Table 1. They were
typical of patients with advanced small-cell lung cancer. All the
patients had extensive-stage disease, nine with lymph node
involvement, eight with liver metastases, three with bone metas-
tases, three with lung involvement and six with other disease sites.
Four patients were previously untreated. Among 17 patients who
had received prior chemotherapy, one had also been treated by
surgery, 13 by radiotherapy and two had received two prior regi-
mens. The median (range) interval from previous chemotherapy
was 139 (20-842) days. Patients were assessed by clinical exami-
nation and chest radiography at each treatment cycle and under-
went full staging evaluation at every second treatment cycle. Full
blood count, biochemistry and assessment of adverse effects were
performed weekly throughout treatment.
'TOMUDEX' is a trademark, the property of Zeneca Limited.
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Table 1 Patient characteristics
Number 21
Gender 16 Male, 5 female
Median age (range) (years) 59 (33-74)
WHO performance status (n)
Grade 0 4
Grade 1 15
Grade 2 2
Prior treatment (n)
None 4
Chemotherapy only 3
Surgery + chemotherapy 1
Chemotherapy + radiotherapy 13
Table 2 Toxicity of raltitrexed treatment, shown as worst WHO grade in 21
patients
WHO grade
0 1 2 3 4
Leucopenia 16 1 0 2 2
Anaemia 19 0 1 0 1
Thrombocytopenia 20 0 0 0 1
Haemorrhage 18 1 1 0 1
Nausea and vomiting 12 5 2 2 0
Mucositis 18 1 2 0 0
Diarrhoea 18 0 3 0 0
Raltitrexed treatment and toxicity
Forty-one cycles of raltitrexed treatment were given (median two
cycles, range 1-4). No dose reductions or delays occurred. The
principal toxicities are shown in Table 2. The most commonly
reported side-effects of raltitrexed treatment were nausea and
asthenia (five patients), although vomiting was reported by only
four patients. Mucositis, diarrhoea and reversible increases in liver
transaminases were also reported. There were no episodes of
neutropenic sepsis. Four patients died within 3 weeks of receiving
raltitrexed. In only one of these cases was a drug-related adverse
event (thrombocytopenia) implicated. The other deaths were
attributed to progressive cancer.
Responses
Among the 21 patients, no objective response was documented,
three patients had stable disease, 16 had progressive disease and
two died of disease. The median time to progression was 6 weeks
(range 1-10 weeks). Ten patients went on to receive further cyto-
toxic chemotherapy. Of these, one achieved a PR, three had stable
disease and five had progressive disease on their next
treatment regimen. The median survival from study entry was
15 weeks (range 2-126 weeks).
DISCUSSION
This phase II study indicates that raltitrexed given in this schedule
is inactive in advanced small-cell lung cancer (96% certainty that
the response rate is < 20%). The difficulties of assessing new
drugs in tumours, such as small-cell lung cancer, that rapidly
develop drug resistance have been widely debated (Cullen, 1989;
Ettinger, 1990; Moore and Kom, 1992). Most investigators now
favour testing new drugs for small-cell lung cancer in chemonaive
patients with extensive disease or those who have relapsed after a
previous response to chemotherapy. This was the group selected
for inclusion in this study. Despite this, these patients had
chemoresistant disease as indicated by a single disease response to
subsequent conventional cytotoxic agents. The time to progression
and overall survival are those expected for such patients.
Raltitrexed was well tolerated in this study. In previous studies,
diarrhoea had been troublesome (Clarke et al, 1996). Here, no
WHO grade 3 or 4 diaffhoea was reported, and no dose modifica-
tions were required. Only one patient died with persistent throm-
bocytopenia. This 51-year-old man had completed cranial and
thoracic irradiation, and chemotherapy with cisplatin, ifosfamide
and etoposide 10 weeks before study entry. He developed throm-
bocytopenia (platelets 24 x109 1-') and moderate leucopenia
(WBC 1.9 x 109 1-') 15 days after a second raltitrexed dose. The
leucopenia recovered, but he was persistently thrombocytopenic at
the time of his death from small-cell lung cancer on day 34.
Raltitrexed has shown promising activity in colorectal and
breast cancers. We conclude that it is not effective as a second-line
agent in advanced small-cell lung cancer. From these data, it
would be difficult to justify a further study in chemonaive patients
with extensive-stage small-cell lung cancer.
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